Video Series

Video 2 - "Exploring Therapies for Platinum Sensitive & Platinum-Resistant Ovarian Cancer"

March 11th 2024

Tailored Therapy: Decision Making for Ovarian Cancer Treatment

A medical expert discusses treatment decision-making and modalities for ovarian cancer, including palliative care and hospice.

March 11th 2024

MIRASOL trial and DESTINY-PanTumor02 Trial Overview

Ronald D. Alvarez, MD, MBA, gives an analysis of the MIRASOL and DESTINY-PanTumor02 trials, including a comparison of study arms and discussion of HER2/neu targeting.

March 11th 2024

Diagnosis and Treatment Timeline: Different Phases of Ph+ ALL Management

The panel provides an overview of the various Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) treatment phases, highlighting the important discussion around inpatient versus outpatient care.

March 11th 2024

Screening and Diagnosing of Ph+ ALL in Adults

The panel discusses optimal strategies for screening and detecting Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in patients across different treatment stages.

March 6th 2024

Future of Myelofibrosis: Anticipated Data and Emerging Therapies

Aaron Gerds, MD, MS, explores the future landscape of myelofibrosis with insights from the 2003 ASH Annual Meeting and Exposition (ASH 2023), and delves into anticipated data on combination therapies and ongoing trials shaping the next phase of myelofibrosis treatment.

March 5th 2024

Unraveling Type 1 Diabetes: Differences Between Type 1 and Type 2

Robert Gabbay, MD, PhD, delineates key differences between type 1 and type 2 diabetes, including autoimmune antibodies, insulin resistance, and insulin deficiency.

March 5th 2024

Review of Clinical Evidence for Delandistrogene Moxeparvovec for DMD

Jessica Nance, MD, MS, reviews the data and evidence that led to accelerated approval of delandistrogene moxeparvovec-rokl for the treatment of ambulatory pediatric patients aged 4 through 5 years with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene.

March 5th 2024

Developments in Muscular Dystrophy Gene Therapy

Emma Ciafaloni, MD, FAAN, dives into the latest developments in gene therapy for muscular dystrophies, focusing on Duchenne muscular dystrophy, and discusses challenges, genetic causes, and the transformative potential of gene therapies.

March 4th 2024

Exploring Therapies for Platinum Sensitive & Platinum-Resistant Ovarian Cancer

A medical expert discusses efficacy of approaches such as carboplatin doublets, checkpoint inhibitors, and PARP inhibitors for patients with platinum sensitive and platinum-resistant ovarian cancer.

March 4th 2024

Innovation vs Access: Supporting Underserved Communities

Pam R. Taub, MD, FACC, FASPC, highlights disparities in access to effective evidence-based therapies for minorities, emphasizing the gap between innovation and access.

March 4th 2024

Disparities in Cardiovascular Care for Diverse Populations

Nihar Desai, MD, MPH, introduces the panel of medical professionals and moderates a discussion on disparities in cardiovascular care among minority populations.

March 4th 2024

Supporting Ph+ ALL Patient: Emotional Challenges and Quality of Life

The panel highlights the quality of life and emotional challenges faced by patients diagnosed with Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL).

March 4th 2024

Timely Detection: Incidence and Prevalence of Ph+ ALL

Vivian Tambe Ebot-Tar, PharmD, MBA, guides a discussion on the incidence of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) and how payers can have the most impact through early treatment coverage.

March 1st 2024

Emerging Agents and Clinical Perspectives in ER+/HER2- Metastatic Breast Cancer

Experts discuss oral SERDs in the pipeline, clinical pathways for treatment of breast cancer, and strategies to help ensure patients have access to treatment. The participants also describe diverse agents in development, including their toxicity profiles.

February 28th 2024

Empowering Desmoid Tumor Patients: Education and Resources

Gain insights into valuable educational resources for patients coping with desmoid tumors, such as global consensus papers and advocacy group websites, and the significance of seeking multiple expert opinions for informed decision-making.

February 28th 2024

Watchful Management and Patient Support for Desmoid Tumors

Delve into the impact of observing desmoid tumors and strategies for maintaining patient well-being during treatment, and learn about the importance of education, shared decision-making, and balancing conservative vs aggressive treatment.

February 28th 2024

Monitoring Myelofibrosis Treatment Response: Guidelines and Considerations

Aaron Gerds, MD, MS, reviews the National Comprehensive Cancer Network (NCCN) guidelines for monitoring myelofibrosis treatment response and delves into crucial aspects like patient impressions, physical examinations, and symptoms.

February 28th 2024

Psychosocial Impact and Pain Management for Desmoid Tumors

Delve into the psychosocial aspects and pain management challenges for patients with desmoid tumors as experts address anxiety, depression, and effective pain control strategies for improved quality of life.

February 27th 2024

Shifting the Treatment Paradigm in Spinal Muscular Atrophy

Emma Ciafaloni, MD, FAAN, explores the groundbreaking approval of onasemnogene abeparvovec-xioi for spinal muscular atrophy and its impact on the treatment paradigm for this rare disease.

February 27th 2024

Evaluating Transformative Gene Therapies

Ryan Haumschild, PharmD, MS, MBA, and Mary Pak, MD, FACP, consider FDA-approved gene therapies for hemophilia, spinal muscular atrophy, and Duchenne muscular dystrophy, exploring their genetic foundations, the FDA approval process, and considerations for therapeutic value and cost.

February 26th 2024

NCCN Guidelines: Implementing New Therapy Options for Ovarian Cancer

Ronald D. Alvarez, MD, MBA, discusses challenges in implementing updated NCCN guidelines, such as coverage limitations imposed by payers.

February 23rd 2024

Elacestrant: Adverse Effects and Their Management, and Impact of Treatment on Quality of Life

Experts discuss the impact of elacestrant on patient well-being, including potential cardiovascular and gastrointestinal toxicities, quality of life, and patient feedback regarding access to treatment.

February 21st 2024

Managing Desmoid Tumor Challenges

Explore effective approaches in handling fatigue, insomnia, and financial difficulties of patients with desmoid tumors as experts highlight psychosocial support and treatment considerations for quality care.

February 21st 2024

Key Considerations for Treating Patients Diagnosed With CLL and SLL

Medical experts provide their final thoughts regarding key treatment considerations for CLL and SLL.

February 21st 2024

Optimizing BTKi Treatment Strategies

The panelists provide perspectives on critical aspects of the CLL and SLL treatment landscape.

February 21st 2024

Other Clinical Considerations in Demodex Blepharitis Treatment

Eric D. Donnenfeld, MD; underscores the significance of an FDA approved treatment for Demodex blepharitis as well as past alternative treatments.

February 21st 2024

Integrating Momelotinib: NCCN Guidelines and Drug Comparison

Aaron Gerds, MD, MS, explores the FDA approval of momelotinib and its swift integration into National Comprehensive Cancer Network (NCCN) guidelines. He reviews different JAK inhibitors based on adverse effects and treatment goals, addressing potential treatment-related anemia in myelofibrosis.

February 21st 2024

Desmoid Tumors: Impact and Quality of Life

Explore the multifaceted impact of desmoid tumors on patients’ physical, functional, and psychosocial well-being as experts emphasize effective symptom management and quality-of-life enhancements.

February 20th 2024

Navigating Gene Therapy Eligibility: The Role of Genetic Testing

Kimberly C. Chen, DO, MSHLM, dives into the role of genetic testing in identifying patients eligible for gene therapy and explores coverage criteria, clinical validity, and utility considerations crucial for payers and managed care executives.

February 20th 2024

Viral Vectors in Gene Therapy

Emma Ciafaloni, MD, FAAN, describes the key differences among viral vectors used in gene therapy, highlighting their applications and strengths in targeting specific diseases.

...

12 13 14 15 16 17 18 19 20

...

48 >